key: cord-0863398-rf0aim7z
authors: Xiong, Qiutang; Xu, Ming; Li, Jiao; Liu, Yinghui; Zhang, Jixiang; Xu, Yu; Dong, Weiguo
title: Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study
date: 2020-09-23
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.09.023
sha: 128e9fe82ec1a6153395a6999ebd2147391f149f
doc_id: 863398
cord_uid: rf0aim7z

OBJECTIVES: To describe the prevalence, nature, and risk factors for the main clinical sequelae in COVID-19 survivors who have been discharged from the hospital for more than 3 months. METHODS: This longitudinal study was based on a telephone follow-up survey of COVID-19 patients hospitalized and discharged from Renmin Hospital of Wuhan University, Wuhan, China before March 1, 2020. Demographic and clinical characteristics and self-reported clinical sequelae of the survivors were described and analysed. A cohort of volunteers who were free of COVID-19 and lived in the urban area of Wuhan during the outbreak were also selected as the comparison group. RESULTS: Among 538 survivors (293[54.5%] female), the median age was 52.0 years (IQR 41.0–62.0), and the median time from discharge from hospital to first follow-up was 97.0 days (IQR 95.0–102.0). Clinical sequelae were common, including general symptoms (n=267, 49.6%), respiratory symptoms (n=210, 39%), cardiovascular-related symptoms (n=70, 13%), psychosocial symptoms (n=122, 22.7%) and alopecia (n=154, 28.6%). We found that physical decline/fatigue (P<0.01), post-activity polypnea (P=0.04) and alopecia (P<0.01) were more common in females than in males. Dyspnoea during hospitalization was associated with subsequent physical decline/fatigue, post-activity polypnea and resting heart rate increases, but not specifically with alopecia. A history of asthma during hospitalization was associated with subsequent post-activity polypnea sequela. A history of pulse ≥90 beats per min during hospitalization was associated with resting heart rate increase in convalescence. The duration of viral shedding after COVID-19 onset and hospital length of stay were longer in survivors with physical decline/fatigue or post-activity polypnea than in those without. CONCLUSION: Clinical sequelae during early COVID-19 convalescence were common, and some of these sequelae might be related to gender, age and clinical characteristics during hospitalization.

As of July 3, 2020, the global pandemic caused by COVID-19 had affected more than 10 000 000 people and caused more than 500 000 deaths in over 215 countries or regions worldwide (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports).

There were also a large number of patients who had been cured and discharged from the hospital, and the follow-up time of COVID-19 survivors from China was longer than those in other countries around the world 1 . Early clinical sequelae associated with COVID-19, such as cardiac sequelae, are known to exist in some survivors 2 . The clinical characteristics, treatment and prognosis of COVID-19 have been extensively studied; however the prevalence, nature, duration and related factors of sequelae in J o u r n a l P r e -p r o o f convalescent COVID- 19 survivors have not been studied [3] [4] [5] . Patients who recovered from severe acute respiratory syndrome (SARS) had radiological, functional and psychological abnormalities of varying degrees [6] [7] [8] . Recent studies suggested that COVID-19 patients might have psychiatric sequelae based on the characteristics of SARS and Middle East Respiratory Syndrome (MERS) 9 . However, few studies have systematically investigated the clinical sequelae in the early recovery of COVID-19

survivors, as well as the injury and dynamic changes of these sequelae 10 . Therefore, we performed a longitudinal study to describe the prevalence, nature, and predictors of sequelae in a large cohort of survivors of COVID-19 in Wuhan, China.

This study included inpatients from 20 to 80 years of age from Renmin Hospital of Wuhan University (Wuhan, China) regarded as the COVID-19 survivor cohort. All survivor cohort participants included patients who were diagnosed with COVID-19

according to World Health Organization interim guidance and were cured and discharged from the hospital by March 1, 2020 11 . Thus, the time since discharge from the hospital of all subjects was more than 3 months. Similarly, the discharge criteria for all survivors also followed the WHO interim guidance. We conducted a preliminary screening based on the health status of discharged patients, excluding those with severe and complex underlying diseases or under invasive treatment, as well as women who were pregnant or breastfeeding. The selected survivors were J o u r n a l P r e -p r o o f enrolled in a telephone follow-up study primarily to observe their clinical sequelae in early recovery from COVID-19 (three months after discharge).

We also recruited volunteers who were free of COVID-19 living in the downtown area of Wuhan during the epidemic as a comparison group. To make a comparison, we first recruited volunteers who had similar demographic characteristics of the COVID-19 survivor cohort. We reviewed and screened the information provided by volunteers who were willing to participate in this study. All participants in the comparison group should have been completely grounded at home for more than 3 months and had not done much physical work during the outbreak. We also excluded those who had a complex illness, were currently undergoing medical intervention, or were unable to provide detailed related information. Eligible subjects in the comparison group were asked the same telephone interview questions as those in the survivor cohort as described below.

The ethics committee of Renmin Hospital of Wuhan University approved this study and granted a waiver of informed consent from the study participants.

The demographics, clinical features, laboratory findings, treatments and outcomes of the participants in the hospital were collected from the electronic medical record system in our hospital. All data were reviewed by an attending physician and an associate chief physician and were finally verified by the major investigators.

Survivors were systematically contacted by three experienced clinicians via mobile J o u r n a l P r e -p r o o f phone, and the detailed reported symptoms related to below key points were recorded.

Any remaining or newly occurring symptoms three months after discharge from the hospital were recorded as sequelae. The survivors' current symptoms were closely distinguished from those of his or her pre-illness state or other underlying diseases not related to COVID-19. The course of the reported symptoms of the survivors were also investigated and documented in detail. 

Continuous and categorical variables are presented as the median (IQR) and n (%), respectively. We used the χ² test or Fisher's exact test to compare differences between the survivor cohort and the comparison group where appropriate. We used the Mann-Whitney U test, χ² test, or Fisher's exact test to compare differences between patients with and without sequelae where appropriate. To explore the risk factors associated with the occurrence of sequelae, multivariable logistic regression models were used. We chose the variables with significant differences that showed no statistical significance but may be highly associated with the occurrence of sequelae to enter the risk factor analysis. Analyses were performed using R software, version 3.6.1 (R Foundation for Statistical Computing). P (two-tailed) < 0.05 was considered statistically significant. participants in the comparison group after screening and culling. A detailed study sample is shown in Figure 1 .

The 

Based on follow-up results, we found that 267 (49.6%) of the 538 COVID-19

survivors had one or more general symptoms, with 152 (28.3%) cases reporting physical decline or fatigue ( Table 2 ). Most patients who reported these symptoms improved, but 35 survivors reported no improvement. A total of 127 (23.6%) survivors complained of excessive sweating (Table 2) . Twenty-four patients reported significant myalgia. Forty-one (7.6%) patients reported joint pain, most commonly in the knee joint (29 cases) but also in the elbow, ankle, wrist and spinal joints.

Twenty-five (4.6%) patients complained of chilliness, such as not being able to face cold air, which was not noticed until they were discharged from the hospital ( Table 2) .

Except for dizziness, the prevalence of all general symptoms was significantly higher in the survival group than in the comparison group (all P <0.05, Table 2 ).

A total of 210 (39%) survivors had one or more respiratory symptoms. The most common polypnea was post-activity polypnea (115 [21.4%]), which they reported was caused just by mild activity ( Table 2) . Except for sputum, the prevalence of all respiratory symptoms was significantly higher in the survival group than in the comparison group (all P <0.05, Table 2 ).

Seventy (13%) survivors reported significant cardiovascular symptoms 3 months after discharge. Of the 60 people who reported significantly higher resting heart rates than before suffering from COVID-19, 45 (75%) of them had resting heart rate increases during their hospitalization and are still present. Twenty-six (4.8%) patients said they occasionally had palpitations (Table 2) . Notably, seven patients said they had recently been diagnosed with high blood pressure and are now taking blood-pressure-lowering drugs ( Table 2 ). The prevalence of high resting heart rates was significantly higher in the survival group than in the comparison group (P <0.05, J o u r n a l P r e -p r o o f Table 2 ).

Ninety-five (17.7%) showed sleep disorders since the onset of the disease, mainly manifested as difficulty falling asleep, short and interrupted sleep ( Table 2) .

Twenty-three (4.3%) people complained of depression and loss of interest in things around them. Nine (1.7%) survivors reported feeling dysphoria after falling ill. Except for dysphoria and inferiority, the prevalence of all psychosocial symptoms was significantly higher in the survival group than in the comparison group (all P <0.05, Table 2 ).

Alopecia was another common sequela during our investigation, observed in 154 survivors (12 males and 142 females, Table 2 ). In the comparison group, however, none reported alopecia. The prevalence of this sequela in women was as high as 48.5% (Table 3 ). Of these, 112 patients reported alopecia starting after discharge from the hospital, and 42 appeared during hospitalization. In 30 patients, symptoms of hair loss improved.

After observing the sequelae prevalence of COVID-19 patients, we focused on the clinical characteristics of the sequelae with high prevalence, including physical decline/fatigue, post-activity polypnea, resting heart rate increases and alopecia. Table   3 shows the univariate analyses of differences in demographic, clinical, and laboratory features during acute COVID-19 and sequelae reported at the first telephone follow-up. Sequelae were more common in females, except for high resting J o u r n a l P r e -p r o o f heart rate. In an additional exploratory analysis, dyspnoea during hospitalization was associated with subsequent physical decline/fatigue, post-activity polypnea and resting heart rate increases, but not specifically with alopecia. A history of asthma during hospitalization was associated with subsequent post-activity polypnea sequela.

A history of pulse ≥ 90 beats per min during hospitalization was associated with resting heart rate increase symptoms in convalescence. The duration of viral shedding after COVID-19 onset and hospital length of stay were longer in survivors with physical decline/fatigue or post-activity polypnea than in those without.

Survivors of COVID-19 are significantly more likely to develop clinical sequelae three months after discharge from the hospital than those without COVID-19

infection. This is true not only for general and respiratory symptoms but also for cardiovascular and psychosocial symptoms. This suggests that these symptoms may indeed be the sequelae of recovery for COVID-19 survivors.

We found that 49.6% of patients who had recovered from COVID-19 still had one or more common symptoms, including physical decline, fatigue and myalgia, 3 months after discharge. Respiratory sequelae were also common in early recovery from COVID-19. Most of these symptoms had been present during hospitalization, as has been reported in many studies 3, 14, 15 . Fortunately, most survivors reported that these symptoms improved over time. However, persistent symptoms, such as joint pain, limb oedema, chest pain and cough, deserve further attention.

The early sequelae of severe SARS and Ebola virus disease (EVD) showed similar symptoms, such as fatigue, asthma and arthralgia 6, 12 . The respiratory sequelae of COVID-19 may be less severe than those of SARS and EVD 6, 12 . Patients in our study did not undergo respiratory function examinations, and the specific degree of functional decline is not clear. Instead, they only compared their perception with their previous respiratory function from a subjective perspective. Further studies are needed to assess the duration of COVID-19 damage to respiratory organs and functions.

Studies have shown that cardiac injury is a common condition among hospitalized patients and is associated with a higher risk of in-hospital mortality [16] [17] [18] [19] .

This may be related to angiotensin converting enzyme 2 (ACE2) acting as the receptor for SARS-CoV-2 2, 20, 21 . Our study found that 13% of patients had cardiovascular sequelae, the most important of which was increased resting heart rate.

In addition, seven patients reported a recent diagnosis of hypertension following COVID-19 infection. These findings may be evidence of COVID-19's long-term damage to the cardiovascular system. The longer-term cardiac effects remain to be investigated. Only a small number of people showed symptoms such as depression and anxiety. It should be noted that our psychosocial queries were limited to those who were willing to describe their psychosocial states to us, and not all of them were willing or able to accurately describe this anomaly. Accurate data may require more detailed questioning or support with questionnaires and psychometric scales.

Finally, we found that alopecia may be a unique sequela of COVID-19 survivors, which has been observed almost exclusively in women. Studies have shown that inflammation is associated with alopecia in women 29 . Whether inflammation from COVID-19 promoted hair loss has not been reported, and its pathogenesis, clinical course and treatment need to be further studied.

Our study is the first to report on the major clinical sequelae J o u r n a l P r e -p r o o f 

Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia

Cardiac sequelae of novel coronavirus disease 2019 (covid-19): A clinical case series

Clinical characteristics of coronavirus disease 2019 in china

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, china

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, china: A descriptive study

Sars: Prognosis, outcome and sequelae

Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: Long-term follow-up

Thin-section ct in patients with severe acute respiratory syndrome following hospital discharge: Preliminary experience

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the covid-19 pandemic. The lancet

Persistent symptoms in patients after acute covid-19

Clinical management of severe acute respiratory infection when novel coronavirus ( 2019-ncov) infection is suspected: Interim guidance

Early clinical sequelae of ebola virus disease in sierra leone: A cross-sectional study

A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during covid-19 outbreak

Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, china: A retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, china

The variety of cardiovascular presentations of covid-19

Association of cardiac injury with mortality in hospitalized patients with covid-19 in wuhan, china

Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in new york city

Out-of-hospital cardiac arrest during the covid-19 outbreak in italy

Covid-19, ace2, and the cardiovascular consequences

Sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor

Understanding and addressing sources of anxiety among health care professionals during the covid-19 pandemic

Psychosocial impact of covid-19

Psychological distress and loneliness reported by us adults

Fear and the 2019-ncov outbreak

The psychological impact of quarantine and how to reduce it: Rapid review of the evidence

Managing mental health challenges faced by healthcare workers during covid-19 pandemic

The impact of economic

All authors declare no conflict of interest.

There were no fundings support this research.J o u r n a l P r e -p r o o f

 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 0.01 14 (8-21) 11 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 0.03 12.5 (8-24.5) 12 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 0. 15 11 (7-18) 12 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) 0